Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 12/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GSR | P00390 | 2/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31123916 | 1.00 | TXNRD1 (0.43) | TXNRD1CYP3A4TSHRHTTALDH1A1 | |
| SCHEMBL17372594 | 0.85 | TXNRD1 (0.48) | TXNRD1CYP3A4TSHRHTTALDH1A1 | |
| SCHEMBL27227490 | 0.83 | TXNRD1 (0.40) | TXNRD1CYP3A4TSHRHTTALDH1A1 | |
| SCHEMBL1428159 | 0.81 | TXNRD1 (0.58) | TXNRD1HTTS1PR4MAPTS1PR1 | |
| SCHEMBL29829685 | 0.81 | TXNRD1 (0.48) | TXNRD1HTTALDH1A1S1PR4MAPT | |
| SCHEMBL27175934 | 0.81 | TXNRD1 (0.48) | TXNRD1HTTALDH1A1S1PR4MAPT | |
| SCHEMBL7836091 | 0.79 | TXNRD1 (0.56) | TXNRD1HTTS1PR4MAPTS1PR1 | |
| SCHEMBL7836089 | 0.79 | TXNRD1 (0.56) | TXNRD1HTTS1PR4MAPTS1PR1 | |
| SCHEMBL7836090 | 0.79 | TXNRD1 (0.56) | TXNRD1HTTS1PR4MAPTS1PR1 | |
| SCHEMBL16126094 | 0.77 | TXNRD1 (0.40) | TXNRD1CYP3A4TSHRHTTS1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688161-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250171463-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. | 2025-05-29 | — | — | US | disclosed |
| EP-4482587-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | Biogen MA Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20240336608-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-10-10 | — | — | US | disclosed |
| WO-2024206357-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-10-03 | — | — | WO | disclosed |
| WO-2023164063-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023164063-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| EP-2776445-B1 | THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-08-10 | — | — | EP | disclosed |
| US-9096614-B2 | Therapeutically active thiazolo-pyrimidine derivatives | UCB PHARMA SA (BE) | 2015-08-04 | — | — | US | disclosed |
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | UCB PHARMA SA (BE) | 2014-10-23 | — | — | US | disclosed |
| EP-2776445-A1 | THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES | UCB Pharma, S.A. (BE) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013068458-A1 | THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | TPMT, IFNG, IRF3 | TXNRD1 350/4885CYP3A4 770/4885TSHR 2062/4885 |
| US-20250171463-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | EBPL, EBP, CREBBP | TXNRD1 1557/4885CYP3A4 4765/4885TSHR 3792/4885 |
| US-20240336608-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL1RN | TXNRD1 3117/4885CYP3A4 436/4885TSHR 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.